PHILADELPHIA, Dec. 23, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, today announced that its raw material supplier has filed its response to questions relating to the Drug Master File (DMF) raised by the U.S. Food and Drug Administration (FDA) for EUR-1008 (ZENTASE(r)), an innovative pancreatic enzyme replacement product (PEP). This filing is in addition to the response that Eurand submitted in August 2008 to the FDA’s questions relating to the manufacture of EUR-1008 in its June 2008 approvable letter.
